Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal Function
Status:
Completed
Trial end date:
2013-03-10
Target enrollment:
Participant gender:
Summary
Shire is developing SSP-004184 (FBS0701), a novel iron chelator , for the treatment of
chronic iron overload in patients with transfusion-dependent hereditary and acquired anemias.
The primary purpose of the study is to assess the pharmacokinetics of SSP-004184 (FBS0701)
following a single 75mg/kg dose of SSP-004184 (FBS0701) in healthy adults and elderly
subjects and in adult subjects with mild, moderate, severe, and end stage renal disease
(ESRD) degrees of impaired renal function. The results of this study will characterize the
pharmacokinetics, safety, and tolerability of SSP-004184 (FBS0701) in adult subjects with
various degrees of renal impairment, and these data will be compared to healthy adult and
elderly subjects.